Financial Performance - The company's revenue for Q1 2025 was ¥162,290,516.78, a decrease of 39.96% compared to ¥270,288,441.14 in the same period last year[4] - Net profit attributable to shareholders was ¥1,064,275.78, down 98.24% from ¥60,565,065.43 year-on-year[4] - The net profit after deducting non-recurring gains and losses was -¥3,411,965.39, representing a decline of 105.71% compared to ¥59,803,967.25 in the previous year[4] - The company reported a total comprehensive income of -¥3,554,830.30 for Q1 2025, compared to ¥52,979,886.88 in Q1 2024[23] - Basic and diluted earnings per share for Q1 2025 were both ¥0.00, compared to ¥0.15 in Q1 2024[23] - The net loss for Q1 2025 was CNY 2,487,647.36, a significant decline compared to a profit of CNY 65,632,514.01 in Q1 2024[31] - The total comprehensive income for the first quarter of 2025 was CNY -2,588,300.46, contrasting with CNY 54,510,490.93 in the first quarter of 2024[32] Cash Flow - The net cash flow from operating activities was -¥68,805,373.58, worsening from -¥7,933,515.62 in the same period last year[4] - Operating cash flow for Q1 2025 was negative at -¥68,805,373.58, compared to -¥7,933,515.62 in Q1 2024[26] - Cash flow from operating activities for Q1 2025 was CNY -68,809,529.80, compared to CNY -7,939,865.44 in Q1 2024, indicating a worsening cash flow situation[35] - The net cash flow from investing activities was -CNY 123,751,836.25, compared to -CNY 86,292,352.83 in the previous period, indicating a significant increase in cash outflow[27] - Cash inflow from financing activities in Q1 2025 was CNY 71,834,374.47, an increase from CNY 44,415,955.34 in Q1 2024[35] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,352,186,880.18, an increase of 2.83% from ¥5,204,868,837.55 at the end of the previous year[5] - The total liabilities increased to ¥1,137,016,519.35 in the latest report, up from ¥987,120,567.56[20] - The total assets as of March 31, 2025, amounted to CNY 5,652,254,361.52, an increase from CNY 5,503,880,417.19 as of December 31, 2024[31] - The total liabilities increased to CNY 1,134,869,744.86 from CNY 984,884,421.21, reflecting a rise in financial obligations[30] Research and Development - R&D investment totaled ¥36,858,462.61, a decrease of 21.48% from ¥46,940,335.50, while the proportion of R&D investment to revenue increased by 5.34 percentage points to 22.71%[5] - R&D expenses for Q1 2025 were ¥36,858,462.61, down 21.5% from ¥46,940,335.50 in Q1 2024[22] - The company is actively pursuing new product development and clinical trials for innovative vaccines, including a new mRNA tumor vaccine[14] - The company has submitted clinical trial applications for its restructured shingles vaccine and adjuvanted flu vaccine, which have been accepted[14] - The company is expanding its product pipeline, including adult vaccines and mRNA technology, to enhance its core competitiveness[14] Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,054[8] - The largest shareholder, Changchun High-tech Industry (Group) Co., Ltd., holds 41.46% of the shares, totaling 171,488,182 shares[9] - Total equity attributable to shareholders was ¥4,215,170,360.83, slightly down from ¥4,217,748,269.99[20] - The company's total equity decreased slightly to CNY 4,517,384,616.66 from CNY 4,518,995,995.98, reflecting a minor reduction in shareholder value[31] Sales and Marketing - The company reported a decline in sales and net profit due to external factors, including reduced demand for the shingles vaccine, with a focus on optimizing marketing strategies[14] - The company plans to expand its sales channels and increase promotional efforts, which contributed to the rise in sales expenses[6] - Sales expenses in Q1 2025 were ¥73,607,698.35, a decrease of 26.3% from ¥99,954,306.04 in Q1 2024[22] - Cash inflow from sales of goods and services in Q1 2025 was CNY 176,473,731.79, down from CNY 253,656,020.12 in Q1 2024, reflecting a decline of approximately 30.4%[34] Future Outlook - The company plans to implement new accounting standards starting from 2025, which may affect future financial reporting[36]
百克生物(688276) - 2025 Q1 - 季度财报